D. E. Shaw & Co., Inc. Adaptimmune Therapeutics PLC Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.43 $19,136 - $38,007	-26,579 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $73,517 - $195,875	-51,411 Reduced 65.92%	26,579 $40,000
Q2 2019 Aug 14, 2019	SELL	$3.23 - $5.41 $699,563 - $1.17 Million	-216,583 Reduced 73.52%	77,990 $314,000
Q1 2019 May 15, 2019	BUY	$3.63 - $6.06 $291,895 - $487,296	80,412 Added 37.55%	294,573 $1.27 Million
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $805,245 - $3.03 Million	214,161 New	214,161 $1.23 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $326,844 - $430,982	-31,367 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $356,796 - $580,924	-50,253 Reduced 61.57%	31,367 $352,000
Q4 2017 Feb 14, 2018	SELL	$6.68 - $8.74 $794 - $1,040	-119 Reduced 0.15%	81,620 $545,000
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $402,973 - $729,929	81,739	81,739 $669,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $108M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.